Sugi Predict

Sugi Predict / Compounds / SCHEMBL402275

SCHEMBL402275

SCHEMBL402275

COC(=O)N1CCN([C@H](C)c2cc(F)cc(NC(=O)Nc3ccc(C)nc3)c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 5/20 0.40
▸ KDR P35968 2/20 0.39
▸ MAPK8 P45983 4/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ PABPC1 P11940 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ HRH3 Q9Y5N1 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ KCNQ3 O43525 1/20 0.38
▸ KCNQ2 O43526 1/20 0.38
▸ FPR1 P21462 1/20 0.37
▸ FPR2 P25090 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ ACKR3 P25106 1/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ CSNK1E P49674 1/20 0.37
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401529 1.00 MAPK10 (0.40) MAPK10KDRMAPK8MEN1PABPC1
SCHEMBL4243861 1.00 MAPK10 (0.40) MAPK10KDRMAPK8MEN1PABPC1
SCHEMBL4237722 0.93 CHRM2 (0.43) MAPK10KDRMAPK8MEN1KMT2A
SCHEMBL398919 0.93 CHRM2 (0.43) MAPK10KDRMAPK8MEN1KMT2A
SCHEMBL402520 0.93 CHRM2 (0.43) MAPK10KDRMAPK8MEN1KMT2A
SCHEMBL401139 0.91 MAPT (0.44) KDRMEN1KMT2AALDH1A1
SCHEMBL402787 0.91 MAPT (0.44) KDRMEN1KMT2AALDH1A1
SCHEMBL3199795 0.90 MAPK10 (0.40) MAPK10KDRMAPK8NPSR1CYP1A2
SCHEMBL4241824 0.90 MAPK10 (0.40) MAPK10KDRMAPK8NPSR1CYP1A2
SCHEMBL3208544 0.90 MAPK10 (0.40) MAPK10KDRMAPK8NPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-8101617-B2 Disubstituted ureas and uses thereof in treating heart failure AMGEN, INC. (US) 2012-01-24 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAPK10 2458/4885KDR 4366/4885MAPK8 3317/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MAPK10 1989/4885KDR 4166/4885MAPK8 2821/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MAPK10 2458/4885KDR 4366/4885MAPK8 3317/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885KDR 4604/4885MAPK8 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.